Skip to main content
Midas Edge

Cogent Biosciences, Inc.

For the period ended Mar 31, 2026. Filed May 5, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 5, 2026

COGT$31.64-5.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share amounts)

Three Months Ended March 31,
20262025
Operating expenses:
Research and development$75,365$63,029
General and administrative28,24211,904
Total operating expenses103,60774,933
Loss from operations(103,607)(74,933)
Other income:
Interest income7,6082,952
Interest expense(1,213)—
Other income (expense), net(140)(5)
Total other income, net6,2552,947
Net loss$(97,352)$(71,986)
Net loss per share, basic and diluted, Series A non-voting convertible preferred stock$(132.58)$(131.22)
Weighted average Series A non-voting convertible preferred stock outstanding, basic and diluted67,41467,892
Net loss per share, basic and diluted, Series B non-voting convertible preferred stock$(530.34)$(524.90)
Weighted average Series B non-voting convertible preferred stock outstanding, basic and diluted4,5166,868
Net loss per share, basic and diluted, common stock$(0.53)$(0.52)
Weighted average common stock outstanding, basic and diluted162,194,778113,307,940
Comprehensive loss:
Net loss$(97,352)$(71,986)
Other comprehensive income (loss):
Net unrealized gains (losses) on marketable securities(770)(283)
Total other comprehensive income (loss)(770)(283)
Comprehensive loss$(98,122)$(72,269)
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.